Cocrystal Pharma (NASDAQ:COCP – Get Free Report) and Enveric Biosciences (NASDAQ:ENVB – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.
Profitability
This table compares Cocrystal Pharma and Enveric Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cocrystal Pharma | N/A | -61.61% | -55.60% |
| Enveric Biosciences | N/A | -383.90% | -204.47% |
Institutional and Insider Ownership
6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 25.6% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 1.2% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Valuation and Earnings
This table compares Cocrystal Pharma and Enveric Biosciences’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cocrystal Pharma | N/A | N/A | -$17.98 million | ($1.74) | -0.97 |
| Enveric Biosciences | N/A | N/A | -$17.29 million | ($6.41) | -0.09 |
Cocrystal Pharma is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and target prices for Cocrystal Pharma and Enveric Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cocrystal Pharma | 0 | 0 | 1 | 0 | 3.00 |
| Enveric Biosciences | 0 | 0 | 1 | 0 | 3.00 |
Cocrystal Pharma presently has a consensus price target of $10.00, suggesting a potential upside of 491.72%. Enveric Biosciences has a consensus price target of $10.00, suggesting a potential upside of 1,691.79%. Given Enveric Biosciences’ higher possible upside, analysts clearly believe Enveric Biosciences is more favorable than Cocrystal Pharma.
Summary
Cocrystal Pharma beats Enveric Biosciences on 5 of the 9 factors compared between the two stocks.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
About Enveric Biosciences
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
